Literature DB >> 10344923

Consensus guidelines for evaluating and treating patients with upper gastrointestinal symptoms in the primary care setting.

M J Whitaker1.   

Abstract

Upper gastrointestinal (UGI) disease represents a significant part of the primary care physician's workload and is ultimately responsible for a major portion of the costs relating to his or her drug prescribing. This paper outlines the scale of the problem and the possibility of a structured management plan for UGI disease. Although this type of strategy is not new, the International Gastro Primary Care Group (IGPCG) has approached it from a practical standpoint that addresses the concerns of general practitioners and the fears and anxieties of patients. In addition, the direct representation of this model with a cost-effective programme is the first opportunity to develop strategies, in primary care, for testing a protocol for the management of UGI disease. The approach is aimed at the primary care setting and is adaptable for use in different cultural groups and healthcare systems.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10344923     DOI: 10.2165/00019053-199814002-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  Prevalence of and risk factors for Helicobacter pylori infection in the western part of Germany.

Authors:  T Breuer; T Sudhop; J Hoch; T Sauerbruch; P Malfertheiner
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-01       Impact factor: 2.566

Review 2.  Clinical economics review: gastroenterology.

Authors:  K Bodger; M J Daly; R V Heatley; D R Williams
Journal:  Aliment Pharmacol Ther       Date:  1996-02       Impact factor: 8.171

3.  The prevalence of peptic ulcer dyspepsia in a rural community in Kenya.

Authors:  I Gatumbi; A D Roy
Journal:  East Afr Med J       Date:  1970-12

Review 4.  Helicobacter pylori.

Authors:  B J Marshall
Journal:  Am J Gastroenterol       Date:  1994-08       Impact factor: 10.864

5.  Dyspepsia and dyspepsia subgroups: a population-based study.

Authors:  N J Talley; A R Zinsmeister; C D Schleck; L J Melton
Journal:  Gastroenterology       Date:  1992-04       Impact factor: 22.682

6.  Accuracy of serology for the diagnosis of Helicobacter pylori infection--a comparison of eight kits.

Authors:  M H Wilcox; T H Dent; J O Hunter; J J Gray; D F Brown; D G Wight; E P Wraight
Journal:  J Clin Pathol       Date:  1996-05       Impact factor: 3.411

7.  Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.

Authors:  T Lind; S Veldhuyzen van Zanten; P Unge; R Spiller; E Bayerdörffer; C O'Morain; K D Bardhan; M Bradette; N Chiba; M Wrangstadh; C Cederberg; J P Idström
Journal:  Helicobacter       Date:  1996-09       Impact factor: 5.753

8.  Helicobacter pylori and upper gastrointestinal disease: a survey of gastroenterologists in the United Kingdom.

Authors:  R Milne; R P Logan; D Harwood; J J Misiewicz; D Forman
Journal:  Gut       Date:  1995-09       Impact factor: 23.059

9.  The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study.

Authors:  L Agréus; K Svärdsudd; O Nyrén; G Tibblin
Journal:  Scand J Gastroenterol       Date:  1994-02       Impact factor: 2.423

Review 10.  Definitions of dyspepsia.

Authors:  R C Heading
Journal:  Scand J Gastroenterol Suppl       Date:  1991
View more
  3 in total

1.  Computer modelling. The need for careful evaluation and public audit.

Authors:  A Maynard; R F Cookson
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

2.  Conceptual framework for standard economic evaluation of physical activity programs in primary prevention.

Authors:  Silke B Wolfenstetter
Journal:  Prev Sci       Date:  2011-12

3.  Modelling different approaches to the management of upper gastrointestinal disease.

Authors:  A K Duggan
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.